Multicenter study of venetoclax-based combined regimen in treatment of adult acute myeloid leukemia
10.3760/cma.j.cn115356-20220110-00011
- VernacularTitle:含维奈克拉联合方案治疗成年人急性髓系白血病多中心研究
- Author:
Yueting HUANG
1
;
Long LIU
;
Tianbi LAN
;
Aizhen CHEN
;
Guixiang WU
;
Zhifeng LI
;
Yiming LUO
;
Jintao ZHAO
;
Yong ZHOU
;
Yun LIN
;
Zhihong FANG
;
Weilin XIA
;
Lian YU
;
Yirong JIANG
;
Bing XU
Author Information
1. 厦门大学附属第一医院血液科，厦门 361003
- Keywords:
Leukemia, myeloid, acute;
Treatment outcome;
Venetoclax
- From:
Journal of Leukemia & Lymphoma
2022;31(7):397-401
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy of venetoclax-based combined regimen in treatment of adult patients with acute myeloid leukemia (AML).Methods:The data of 50 adult AML (non-acute promyelocytic leukemia) who received venetoclax-based combined regimen in the First Affiliated Hospital of Xiamen University, Dongguan People's Hospital, the First Hospital of Longyan City, Jieyang People's Hospital from December 2018 to May 2021 were retrospectively analyzed. Different doses venetoclax combined with demethylation drugs or low-dose chemotherapy regimen were used to analyze the therapeutic efficacy. The related factors influencing efficacy were analyzed by using logistic regression.Results:The composite complete remission (CR) rate of 50 AML patients was 62.0% (31/50), the overall response rate (ORR) was 76.0% (38/50); 28 patients achieved effectiveness [CR and partial remission (PR)] after the first cycle and could achieve effectiveness by 3 courses of treatment at the latest. Among 50 patients, 28 cases were newly diagnosed AML, the composite CR rate was 60.8% (17/28), ORR was 78.6% (22/28); 22 cases were recurrent and relapsed, the composite CR rate was 63.6% (14/22), ORR was 72.7% (16/22); and there was no statistically significant difference of ORR between the both groups ( χ2 = 0.23, P = 0.743). Logistic regression multivariate analysis showed age was the only independent influencing factor for the treatment effectiveness ( OR = 8.451, 95% CI 1.306-54.697, P = 0.025). The median duration time of patients receiving venetoclax treatment regimen was 4.5 months (1.1-15.0 months); 16 cases who had treatment effectiveness finally relapsed, the median time of maintaining effectiveness was 5 months (1.1-11.0 months). Additionally, the common treatment-related adverse reactions included bone marrow suppression after treatment, followed by some gastrointestinal reactions like nausea, vomiting and stomachache. In addition, no patient stopped medication for more than 1 week due to bone marrow suppression related complications. Conclusion:Venetoclax-based combined regimen shows a good short-term efficacy in treatment of AML. It is also effective and tolerable for elderly patients receiving reduced dose therapy.
